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30. voltage…………………………………………………...……..........................(V) 
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LIST OF MOLECULAR FORMULA  
&  
FUNCTIONAL GROUPS 
 
 
 
1. 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid……….……......(HEPES) 
2. Acetamide groups………………………………………..……...(-NHCOCH3) 
3. Amino group………………………………………………………........(-NH2) 
4. Calcium carbonate…………………………………………………….(CaCO3) 
5. Carbon………………………………………………………………...…....(C) 
6. Carbon-Hydrogen bond………………………………………..………….(CH) 
7. Carbon-Oxygen bond……………………………………...…………….(C=O)  
8. Hydrochloric acid………………………………………………………..(HCl) 
9. Hydrogen……………………………………………………...……………(H)   
10. Hydrogen bond…………………………………………………………..(-OH) 
11. Hydroxymethyl group………………………………………………..(CH2OH) 
12. Potassium chloride……………………………………….………………(KCl) 
13. Potassium hydroxide…………………………….………………….…..(KOH) 
14. Potassium permanganate…………….…………………………...…..(KMnO4) 
15. Nitrogen……………………………………………………...……………..(N) 
16. Oxalic acid…………………………………………………………...(H2C2O4) 
17. Sodium hydroxide……………………………………………....……..(NaOH) 
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PEMAHAMAN MEKANISMA SEL PLATELET UNTUK MENGANALISA 
KEBERKESANAN KITOSAN TERHADAP PENYAKIT  
VON WILLEBRAND IN VITRO 
 
ABSTRAK 
 
Biobahan kitosan diperolehi daripada cengkerang hidupan laut mempunyai potensi 
yang besar bagi kegunaan klinikal kerana ia dapat bertindak balas dengan sel-sel 
platelet secara bebas untuk membantu proses pembekuan darah. Penyelidikan ini 
mengesahkan keupayaan biobahan kitosan untuk merangsangkan mekanisma platelet 
dari penderma darah normal dan pesakit von Willebrand disease (vWD) in vitro. 
Eksperimen ini meliputi kajian kebolehan degradasi; platelet: lekatan, pengaktifan, 
penggumpalan; analisis pembekuan darah dan analisa pengantara hemostatik: von 
Willebrand Factor (vWF), Faktor 8 (FVIII), Thromboxane A2 (TXA2), P2Y12, 
glycoprotein IIbIIIa (GpIIbIIIa), Transforming Growth Factor- Beta 1 (TGF-β1), 
dan Platelet Derived Growth Factor-AB (PDGF-AB). Kajian perbandingan telah 
dijalankan dengan menggunakan dua jenis kitosan yang terdiri daripada 7% N,O-
Carboxymethylchitosan (NO-CMC) (dengan 0.45 mL kolagen), 8% NO-CMC, Oligo-
chitosan (O-C) dan O-C 53. Kajian ini dijalankan dengan menggunakan teknik-
teknik ujikaji seperti enzyme-linked immunosorbent assay, westergren, coagulation 
analyzer, platelet aggregometery, western blotting, flow cytometry, scanning 
electron microscopy, light microscopy and automated hematology analyzer. Seramai 
14 orang pesakit von Willebrand (vWD) dan individu biasa telah direkrutkan dalam 
kajian ini. Hasil kajian ini menunjukkan bahawa kitosan jenis O-C mempunyai ciri- 
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ciri biodegradasi serta memiliki keliangan (scaffold) yang lebih baik. Liang scaffold 
ini membolehkan nutrien dan sel-sel menembus keluar dengan menggalakkan aktiviti 
platelet bagi mempercepatkan proses hemostasis dan proses penyembuhan luka.      
O-C memberi implikasi positif dengan menyebabkan platelet melekat, mengaktifkan, 
menggumpal serta membentuk rangkaian fibrin larut untuk mengukuhkan 
pembentukan platelet plug dengan merangsangkan platelet mediators yang dikaji. 
Berdasarkan hasil kajian yang diperolehi, kebanyakan pesakit di Malaysia 
dipengaruhi oleh penyakit vWD Jenis I. Memang tidak dapat dinafikan biobahan 
kitosan yang terdiri daripada kumpulan oligo mempunyai potensi yang mampu 
merangsangkan mekanisma platelet terhadap pesakit vWD. Kitosan O-C berpotensi 
memulakan tindakan platelet dan dikesan mempercepatkan proses pembekuan darah. 
O-C mampu menggalakan expresi reseptor vWF & FVIII antigenicity dan TXA2 bagi 
tujuan proses penggumpalan platelet. Dalam pada masa yang sama, analysis 
GpIIbIIIa dan P2Y12 juga menunjukkan yang kitosan kumpulan O-C boleh 
mengaktifkan activiti platelet dengan menyediakan permukaan membran yang baik 
untuk memudahkan generasi thrombin. Seterusnya, O-C juga boleh merangsangkan 
pembebasan faktor pertumbuhan, terutamanya TGF-β1 dan PDGF-AB. vWD adalah 
kelaziman gangguan pendarahan, dan kebanyakan pesakit memiliki penyakit vWD 
jenis I. Kitosan kumpulan Oligo berpotensi mampu mencetuskan platelet 
thrombogenicity cascades pada pesakit vWD. Kitosan berpotensi memulakan 
tindakan platelet dan dengan itu mempercepatkan proses hemostatik melalui 3 proses 
utama: lekatan platelet, pengaktifan dan pengumpulan. Kitosan O-C dan O-C 53 
berfungsi lebih baik daripada jenis NO-CMC kitosan dalam mengaktifkan aktiviti 
platelet untuk membentuk hemostatik plug di kalangan penderma normal dan pesakit 
vWD in vitro. 
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UNDERSTANDING PLATELET THROMBOGENICITY CASCADE OF THE 
BIODEGRADABLE CHITOSAN DERIVATIVES IN  
VON WILLEBRAND DISEASE IN VITRO 
 
ABSTRACT 
 
Chitosan has become one of the most promising local hemostatic agents because it is 
of particular interest as it functions independently on platelets and normal clotting 
mechanisms. The present study was designed with the aim to test the ability of the 
mechanisms of blood platelets towards the action of biodegradable chitosan in 
normal donors and von Willebrand disease (vWD) patients in vitro. This work 
determined the underlying mechanism of chitosan-induced platelet thrombogenicity 
and comprises experimental tests such as degradation ability; platelet: adhesion, 
activation: aggregation; coagulation analysis and hemostatic mediators: von 
Willebrand Factor (vWF), Factor 8 (FVIII), Thromboxane A2 (TXA2), P2Y12, 
glycoprotein IIbIIIa (GpIIbIIIa), Transforming Growth Factor- Beta 1 (TGF-β1) and 
Platelet Derived Growth Factor-AB (PDGF-AB). Comparative studies have been 
conducted to measure the hemostatic capacity of biodegradable 7% N,O-
Carboxymethylchitosan (NO-CMC) (with 0.45 mL collagen), 8% NO-CMC, Oligo-
chitosan (O-C) and O-C 53. Lyostypt, the topical hemostatic agent was used as a 
positive control. This study was conducted using enzyme-linked immunosorbent 
assay, westergren, coagulation analyzer, platelet aggregometery, western blotting, 
flow cytometry, scanning electron microscopy, light microscopy and automated 
hematology analyzer techniques. Fourteen vWD and normal donors were recruited in  
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this study with provided informed written consent. O-C type of chitosans are able to 
enzymatically degrade and possess better porosity to allow nutrients and cells to 
enter to accelerate hemostasis and wound healing process. O-Cs exert a combined 
effect on thrombogenesis by causing platelets to adhere, activate, aggregate and 
forms fibrin network to strengthen platelet plug formation by elevating the studied 
mediators. O-C was capable to induce the expression levels of vWF and FVIII 
antigenicity and TXA2 receptor signals. This signaling pathway assists the platelet 
aggregation. Also, GpIIbIIIa and P2Y12 analysis showed that O-C group of chitosan 
are capable of activating platelets by providing a good surface for blood hemostatic 
mediators and signals to facilitate thrombin generation. O-C-activated platelets lead 
to the release of growth factors, mainly TGF-β1 and PDGF-AB. Therefore, this 
exhibited that greater expression level of O-C group of chitosan assists in mediating 
wound healing process. vWD is the low prevalence hereditary bleeding disorder 
occurs in Malaysia, and most patients belong to vWD type I. Oligo group of 
chitosans are potentially capable to trigger platelet thrombogenicity cascades in vWD 
patients. Tested chitosan-stimulated-mediators potentially initiate the platelet actions 
and thus expedite the hemostatic processes via 3 major processes: platelet adhesion, 
activation and aggregation. This study demonstrated that the greater expression level 
of O-C assists in elevating platelet thrombogenicity cascades to achieve hemostasis. 
Biodegradable O-C and O-C 53 type of chitosan worked better than NO-CMC types 
of chitosan in activating platelet activities to form the hemostatic plug in normal 
donors and vWD patients in vitro. 
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CHAPTER    1 
 
                                                      INTRODUCTION 
1.1 Blood 
Blood is deemed so precious because it is the basic necessity for health since our body 
needs a steady provision of oxygen to reach billions of tissues and cells (Table 1.1)  
 
Table 1.1   Blood physiology 
Produced in Bone marrow 
Derived from Hematopoietic stem cells (HSC / HSCs) 
Physical characters Denser, more viscous than water, sticky 
Temperature 37 Celsius (°C) 
pH 7.35-7.45 
Consists of 20% extracellular fluid, 8% of total body mass 
Made up of Cellular elements  (37-54 %)  Formed elements [red blood cells 
(RBC/ RBCs), white blood cells (WBCs) and platelets] 
Extracellular matrix (ECM)  (46-63 %)  Plasma 
Osmolality 275-295 milliosmoles per kilogram (mOsm/kg) 
Blood volume Male     : 5-6 litres (L)  
Female : 4-5 L 
Major functions  i)  Transports   – Oxygen from lungs to the cells of body, carbon 
      dioxide from blood cells to the lungs, nutrients, waste products 
ii)  Regulates     – pH of all body fluids; Maintain homeostasis  
iii) Protects       – From excessive loss of blood after an injury;    
     against diseases        
 
 
 
 
Source : (Tortora and Derrickson, 2005; Anatomy & Physiology, 2013). 
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1.1.1  Hematopoiesis process 
All blood cells develop from hematocytoblasts. The hematocytoblasts is a type of stem 
cells produces blood cells. Hematopoiesis is the process where immature precursor cells 
develop into mature blood cells. The initial process generating new blood cells begins at 
the very early stage as embryo develops and this continues for the entire life span. 
Embryonic stem cells (ESCs) are characterized by their capability to self-renew 
indefinitely by not losing their pluripotencies. Billions of new blood cells produced in 
the body which derived from the HSCs. HSCs are categorized into long term, short term 
and multipotent progenitors depending on the degree of their self-replenishing abilities.  
Hematopoiesis is the process that generates blood cells of all lineages. Signaling 
pathways such as Wingless-Type MMTV Integration Site Family (WNT) pathway help 
to regulate the stem cells in various types of organs like skin, nervous system and HSC. 
Stimulation of hematopoietic progenitors and stem cells with soluble WNT proteins or 
downstream activators of the WNT signaling leads to the expansion and regulation of 
hematopoietic system. Newly developed blood cells repeatedly originate from 
multipotent HSCs and became committed to the erythroid, megakaryocytic, 
granulocytic, monocytic and lymphocytic lineages. Blood cell formation results from a 
hierarchical progression of differentiation of multipotential HSCs (Robb, 2007; 
Hematopoiesis from multipotent stem cell, 2012). Matured blood cells comprise RBCs, 
WBCs: neutrophil, basophil, eosinophil, lymphocyte, monocyte and platelets (Figure 
1.1; Table 1.2). 
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Figure 1.1 Regulation of hematopoiesis process. This figure shows the evolution 
of different types of cells that arise from HSC to mature blood cells (underlined in red: 
RBCs, WBCs and platelets). The image was adapted and modified from (Hematopoiesis 
from multipotent stem cell, 2012).  
Source: http://www.ebioscience.com/resources/pathways/hematopoiesis-from-
multipotent-stem-cells.htm. 
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1.1.2  Functions of blood 
 
Table 1.2 Classification of 3 different types of blood cells according to their  
own functionality 
Formed element Number  Featured  
characteristics 
Functions  
 
RBCs 
 
4.8x106/ 
microliter 
(µL) in 
females 
5.4x106/µL in 
males 
7-8 micrometer 
(µM)ŧ ; Biconcave 
discs, no nucleus, 
lifespan : 120 days 
Transport most of the 
oxygen and part of the 
carbon dioxide in the 
blood 
 
 
 
Leukocytes / 
(WBCs) 
 
 
Granulocytes 
Neutrophils 
   
 
 
 
 
 
 
 
 
Eosinophils 
   
 
 
 
 
 
 
 
 
 
(5-10)x103/µL 
 
 
 
Of all WBCs: 
 
60-70% 
 
 
 
 
 
 
 
 
 
 
2-4% 
 
 
 
 
 
 
 
 
 
 
 
Live for few hours 
(hr / hrs) to few days 
 
 
 
 
10-12µMŧ, nucleated 
have 2-5 lobes are 
interconnected by 
thin strands of 
chromatin. 
Cytoplasm has very 
fine, pale lilac 
granules  
Lifespan: Minutes 
(min / mins) to days 
 
10-12µMŧ. Nucleus 
has 2 lobes 
connected by a thick 
strand of chromatin; 
large; bright red-
orange granules fill 
the cytoplasm. 
Lifespan: Mins to 
days 
 
 
 
Battle against pathogens 
and foreign substances 
which invades the body 
 
 
 
Involved in phagocytosis 
process and destruction of 
bacterial with lysozyme 
by providing strong 
oxidants, such as 
superoxide anion, 
hydrogen peroxide and 
hydrochlorite anion 
 
 
 
Involved in allergic 
reactions; phagocytized 
antigen (Ag / Ags)- 
antibody (Ab / Abs) 
complexes; destroy 
parasites infections 
 
 
 
 
 
 Table 1.2. Continued 
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Basophils 
    
 
 
 
 
Agranulocytes  
Lymphocytes 
(Lym) 
(T cells, B cells 
and Natural killer 
cells) 
   
 
 
 
 
 
Monocytes 
  
 
0.5-1% 
 
 
 
 
 
 
 
 
20-25% 
 
 
 
 
 
 
 
 
 
8-10µMŧ 
Nucleus has 2 lobes 
but difficult to 
notice the nucleus 
due to heavy dense 
dark purple granules 
Lifespan: Unknown 
 
 
Spheroid cells with 
a single and bigger 
size nucleus  
Small Lym:6-9µMŧ 
Large Lym:10-
14µMŧ. Cytoplasm 
forms a rim around 
the nucleus, appears 
to be in sky blue; 
The larger the cell, 
the more the 
cytoplasm visible 
 
Lifespan: Many 
years; 
12-20µMŧ, nucleus 
kidney shaped  
 
Release heparin, 
histamine and serotonin in 
allergic reactions that 
stimulate the  
inflammatory response  
 
 
 
 
Mediate immune 
responses including Ag-
Ab reactions  
B cells: secrete Abs  
T cells: Attack invasive 
viruses, cancer cells and 
transplanted tissue cells 
Natural killer cells: 
Attack infectious 
microbes and tumor cells 
 
 
 
Effective phagocytic cells 
and act as a garbage 
collecting cells in the 
immune system 
 
Platelets 
 
 
1.4 x 105 – 
4.4 x 105/µL 
 
 
2-4 µMŧ, Contain 
many vesicles and 
has no nucleus.  
Lifespan : 5-9 days 
 
 
Aid in hemostasis process 
by releasing chemicals 
which promotes vascular 
spasm and blood clotting 
 
 
All the information and figures were obtained from: (Tagliasacchi et al., 1997; Manning, 
2004, Tortora and Derrickson, 2006; look for diagnosis, 2009; Connor E and Faraci J, 
2009; Wellsphere, 2010; Medfriendly lymphocytes, 2012; Anatomy & Physiology, 
2013; Circulatory system, 2013; Anatomy blood, n.d.); ŧIndicates in diameter. 
 
 
 
3-8% 
6 
 
1.2 Hemorrhage 
 
Bleeding is the loss of blood from the circulatory system and technically known as 
hemorrhage. Fundamentally, bleeding can occur internally (blood escapes from blood 
vessels or organs) and externally (blood loss through natural opening such as mouth, 
nose, ear, urethra, vagina and anus; through a break in the skin) (Blake, 2014). 
Hemorrhage is the most common cause of death for severely injured patients when 
prompt action was not taken within a critical time period. Over the past 3 decades, 
improved methods have been widely introduced in the civilian settings. Battlefield 
wounds differ from other usual injuries in terms of epidemiology, mechanism of injury 
and pathophysiology of the body’s response (Champion et al., 2003). Forty percent of 
traumatic mortality deaths and up to 90% of all civilian deaths took place in pre-hospital 
settings (Bellamy, 1984; Sauaia et al., 1995). Based on American College of Surgeon’s 
Advanced Trauma Life Support, hemorrhage can be classified into 4 different categories 
depending on the level of severity and the classification is clearly depicted in Table 1.3 
(Manning, 2004). 
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Table 1.3   Classification of hemorrhage levels varying from type 1, 2, 3 and 4 based on 
the volume of  loss, sign & symptoms, volume resuscitation, behavioral changes and 
blood transfusion. Information adapted from Manning, (2004). 
 
Type Volume 
of loss 
Sign & 
Symptoms 
Volume 
resuscitation 
Behavioral 
changes 
Blood 
transfusion 
1 >15% No No No No 
2 15-30% Often 
tachycardiac; 
Skin begin to 
appear pale 
Required with 
crystalloids 
(saline solution 
or Lactated 
Ringer’s 
Solution) 
Moderate No 
3 30-40% Blood pressure 
drops, heart rate 
increase and 
shock 
Required with 
crystalloids 
Moderate to 
severe 
Yes 
4 >40% Body 
compensation is 
reached 
Required 
aggressively 
Severe 
 
Yes 
 
1.3 Platelets  
 
When platelets decrease in number or become malfunction, the risk of hemorrhage is 
very high upon injuries. Platelets, which circulate within the blood, are the essential 
mediators that trigger the mechanical pathway of the coagulation cascade upon 
encountering any damage to the blood vessels. Platelets promote primary (1°) 
hemostasis via 3 major processes: activation, adhesion and aggregation. When the 
integrity of the vascular endothelium is interrupted, various macromolecular elements of 
the vascular subendothelium become exposed and readily accessible to platelets 
(Nakamura et al., 1999). 
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Open canalicular 
System 
 
Table 1.4 Properties, structure, function and mechanism of platelets 
Action   Descriptions 
Platelets   Known as thrombocytes 
Produced from   Very large bone marrow cells called megakaryocytes 
Megakaryocytes   Develop into giant cells to release <1 X 103 platelets/ megakaryocytes 
Circulate   Only 7-10 days 
Structure   2.5µM in average normal diameter, biconvex discoid shape, sticky in    
  nature 
Count   Normally (1.4 x 105) to (4.4 x 105) / µL 
Bleeding risk 
depending on 
the platelet 
counts 
≥50,000 / µL  Minimal  
20,000 – 50,000 /µL  Minor bleeding after trauma 
<20,000 / µL  Spontaneous bleeding 
<5000 / µL  Severe, possibly life threatening  
 
Detailed 
structure: 
 
 
 
 
 
 
 
 
  
 
Formed by invaginations of platelets. Provide a space for platelet 
products to enter 
 
Act as a storage pool. Consists of non-metabolic Adenosine 
triphosphate (ATP) and Adenosine diphosphate (ADP), serotonin and 
calcium (Ca). Platelets release their granules upon activations to 
interact with other platelet cells 
 
Dense   granules 
 
Open Canalicular 
system 
Table 1.4. Continued 
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Glycogen granules 
 
Cytoskeleton 
Alpha granules 
 
Supply the energy source for platelet interactions 
 
Act as the metabolic or cytoplasmic pool. They mainly contains 
Fibrinogen (Fib), thrombospodin, factor 5 (FV), von Willebrand factor 
(vWF), beta-thromboglobuline and factor 4 (FIV). Upon activation, 
platelets release their granules to interact with other platelets 
 
The actin and myosin cytoskeleton organizes a network to sustain the 
platelet’s discoid shape. Upon activation, membrane receptors interlink 
through this network to allow platelets to change shapes into 
pseudopodia forms and eventually release their granule contents 
 
Helps the actin membrane cytoskeleton maintain the discoid shape of 
platelets. Reorganize platelet shape changes, contract internally and 
granules content will release upon platelet activation 
 
An internal smooth endoplasmic reticulum membrane, which helps to 
store Ca to activate platelets and aid in prostaglandin & thromboxane 
(TX) synthesis 
 
Serve as energy source because resting platelets generate their energy 
via oxidative phosphorylations 
 
Contains typical phospholipid bilayer membranes and glycoproteins 
(Gp) and membrane phospholipids allow the coagulation proteins to 
interact 
 
1° function To stop hemorrhage following vascular injury 
 
 
 
Cytoskeleton 
 
 
 
 
 
 
 
Microtubular 
system 
 
 
 
 
 
 
 
 
 
 
 
 
Glycogen 
granules 
 
Alpha granules 
 
Mitochondria 
 
 
 
Cover 
Dense tubular 
system
 
Table 1.4. Continued 
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All the information and figures were adapted from (Periayah et al., 2013; 2014; Platelet 
Research Laboratory, 2014). 
 
 
Other functions Fight microbial infections, trigger inflammation to promote tumor 
angiogenesis and metastasis process, secrete inflammatory mediators 
and aid in wound therapy 
Mechanism  Under normal circumstances, platelets do not adhere to the 
vessel wall. However, upon tissue injury, platelets adhere to the 
ECM by exchanging signals with many receptors and mediators 
to coordinate rolling of platelets to adhere at the sites of 
vascular injury. Firm platelet adhesion stimulates a signaling 
mechanism mediates via tyrosine kinases and G-protein 
coupled receptors, which supports platelet activation, resulting 
in granule release and increasing the number of platelets. 
 Platelet adherences and activations initiate platelet aggregation 
to provide a procoagulant surface engaged in the formation of 
fibrin-rich hemostatic plug at the injured area. Activated 
platelets stimulate endothelial cells to synthesize and secrete 
molecules that control and limit the formation of thrombus. 
Stained smear Appears as a dark purple spot on Geimsa-stained peripheral blood 
smear. Used to study the size, shape, qualitative number and clumping. 
Upon biomaterial adherences, platelets can be fixed in 2.5% 
glutaraldehyde for viewing under a scanning electron microscope 
(SEM) 
Shape changes  
 
(i) Platelet in resting mode (ii) Activated platelets change into a 
pseudopodia shape (iii) Aggregated platelets   (iv) Platelet spreading 
i ii iii iv
v 
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1.4 Hemostasis 
 
 
Hemostasis is a process to prevent hemorrhage by arresting and keeping the blood 
within the damaged vessel walls.  Hemostasis is a complex process that is contingent on 
the complex interaction of platelets, plasma coagulation cascades, fibrinolytic proteins, 
blood vasculatures and cytokine mediators. Upon tissue injury, the hemostatic 
mechanism employs a plethora of vascular and extravascular receptors in accordance 
with the blood components, to seal off the impairments to the vasculature and closing it 
off from the encircling tissues. Normal hemostatic responses can be organized into 6 
different important phases classified under 3 major categories of hemostasis (Kulkarni, 
2004; Stassen et al, 2004; Stroncek and Reichert, 2008; Davidson, 2013; Moake, 2013) 
(Table 1.5). 
 
Table 1.5  Mechanical pathway of 3 different types of hemostasis 
Type of hemostasis Mechanism 
1° hemostasis •Blood vessel contraction /vasoconstriction 
•Platelet plug formation upon platelet adhesion and aggregation 
Secondary (2°) 
hemostasis 
•Activation of the coagulation cascade 
•Deposition and stabilization of fibrin 
Tertiary hemostasis •Dissolution of fibrin clot 
•Dependent on plasminogen activation 
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1.4.1  Vasoconstriction 
 
Vascular spasm occurs whenever there is an injury or damage to the blood vessels. This 
will trigger a vasoconstriction which could eventually stop the blood flow. This reaction 
can respond in up to 30 mins and is localized to the injured area. At this stage, exposed 
collagen fibers will release ATP and other inflammatory mediators to recruit 
macrophages. In addition, the ECM becomes highly thrombogenicity; promoting platelet 
adhesion and aggregation (Figure 1.2) (Kumar et al., 2009; Hidalgo, 2011). 
 
 
 
 
Figure 1.2 Vasoconstriction phase. 1° hemostasis is characterized by 
vasoconstriction, which is the initial phase for stopping the blood flow. The figure was 
extracted from the source: Kumar, V., Abbas A.K. & Aster, J.C. (2009). Robbins and 
Cotran Pathologic Basis of Disease. 9th ed.: Saunders Elsevier. 
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1.4.2 Platelet plug formation 
 
Following vasoconstriction, exposed collagen from the damaged surface will encourage 
platelets to adhere, activate and aggregate to form a platelet plug and sealing off the 
injured area. 
 
 
 
 
Figure 1.3 Platelet plug formation.  Injuries on the endothelial cells highly exposes 
to thrombogenic, subendothelial ECM to ease platelet adherences and activation. Platelet 
activation triggers platelet shape changes by releasing secretory granules. Released 
secretary granules will recruit additional platelets to form platelet plug which is referred 
to as 1° hemostasis. The figure was extracted from the source: Kumar, V., Abbas A.K. & 
Aster, J.C. (2009). Robbins and Cotran Pathologic Basis of Disease. 9th ed.: Saunders 
Elsevier. 
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1.4.2.1  Platelet adhesion  
 
Platelet adhesion mechanism is generally supported by the particular interactions 
between the membrane receptors and the absorbed plasma proteins. The platelet 
membrane receptors are enriched with Gp receptors embedded in the phospholipid 
bilayer including tyrosine kinase receptors, integrins, leucine rich receptors, protein      
G coupled transmembrane receptors, selectins and immunoglobulin domain receptors. 
These are the important proteins involved to facilitate hemostatic function by mediating 
the interactions between cell-platelet and platelet-substrates (Marguerie et al., 1979; 
Andrew et al., 2003; Corum, 2011). The initial event that occurs upon hemostasis is the 
rolling and adherences of the platelets to the exposed subendothelium. Platelet adhesion 
is mediated by vWF which binds to Gp Ib-IX in the platelet membrane.  vWF is a blood 
Gp that serves as an adhesive protein, which could bind to other proteins, especially 
Factor 8 (FVIII) at the wound sites (Packham and Mustard, 1984; Sadler, 1998; Kumar 
et al., 2009; Ruggeri, 2009; Rumbaut and Thiagarajan, 2010). 
 
 
1.4.2.2  Platelet activation  
 
A variety of stimuli can activate platelets. Platelet cells can also be activated upon 
biomaterial surface stimulation. Adhered platelets undergo degranulation and release 
cytoplasmic granules that contain serotonin, platelet activating factors (PAF) and ADP.  
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ADP is an important physiological agonist stored in the dense bodies of platelets that 
play an essential function in normal hemostasis and thrombosis. Platelet are activated to 
change shapes into a pseudopodal form upon the adhesion to the injured area which will 
activate the collagen receptors on their surface membrane named, GpIIbIIIa, to undergo 
release reactions. The GpIIbIIIa complex, organized through Ca-dependent association 
of GpIIb and GpIIIa that is a necessary step in platelet aggregation and endothelial 
adherence (Calvete, 1995; Shattil, 1999). At the same time, platelets tend to synthesize 
and discharge thromboxane A2 (TXA2), aiding in vasoconstriction and platelet 
aggregation. In addition, GpIIbIIIa integrins and P-selectin move from the α-granule 
membrane to the platelet membrane to support platelet aggregation. Additionally, these 
are the receptors that could act as the catalytic surface and facilitate the hemostasis 
process. (Figure 1.4) (Niiya et al., 1987; Comfurius et al., 1996; Gupta, 2013). 
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Figure 1.4 Platelet activation process. The schematic diagram portrays the internal 
organelles with prominent crucial storage contents that are involved in platelet 
activations and aid in platelet aggregation. This figure was adapted from the source: 
Moers, A., Wettschureck, N. & Offermanns, S. (2004).  
 
  
1.4.2.3 Platelet aggregation 
 
Platelet aggregation begins once platelets become activated, triggering the GpIIbIIIa 
receptors (50-100/platelets), which attach to vWF or Fib. Each activated platelet extends 
pseudopods, clumping and becoming aggregated. These activations are further 
heightened by the generation of thrombin via the hemostasis mechanism. Platelet 
aggregation promotes 1° platelet plug. The ADP receptor interconnects with a family of  
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ADP receptors (P2Y1 and P2Y12), which could be detected on platelets as helping with 
aggregation. P2Y1 receptors assist in stimulating the initial platelet shape changes and 
platelet aggregation. At the same time, P2Y12 is an important mediator for blood 
clotting. It increases significantly, responding to ADP to complete the aggregation 
process. Eventually, the formed platelet plug ought to be stabilized by the formation of 
fibrin (Figure 1.5) (Coller et al., 1991; Dorsam and Kunapuli, 2004; Yip et al., 2005; 
Offermanns, 2006; Kumar et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Platelet aggregation phase. Tissue factor (TF) also known as factor 3 
(FIII) and thromboplastin, is a membrane-bound procoagulant. TF acts with factor 7 
(FVII) as the major in vivo initiator of the coagulation cascade to generate thrombin. 
Thrombin adheres with circulating Fib and convert into insoluble fibrin by forming 
fibrin network. This fibrin network strengthens the initial platelet plug. This image was 
extracted from the source: Kumar, V., Abbas A.K. & Aster, J.C. (2009). Robbins and 
Cotran Pathologic Basis of Disease. 9th ed.: Saunders Elsevier. 
 
18 
 
1.4.3 The Coagulation Mechanism 
 
 
Approximately fifty significant substances affect the blood coagulation mechanisms. 
The blood coagulation cascade of 2° hemostasis mainly consist of 2 main pathways. The 
pathways are the intrinsic (contact activation pathway) and extrinsic (TF pathway) 
pathways. The blood clotting process can be classified into 3 important steady steps as 
follows; (i) involvement of a complex cascade, triggering the chemical reactions that are 
mediated by the coagulation factors that respond to form fibrin strands for consolidating 
the platelet plugs; (ii) the conversion of prothrombin (PT) into thrombin which is 
catalyzed by the PT activator; and (iii) conversion of Fib into fibrin, which eventually 
enmeshes the plasma, platelets and blood cells to build a firmer clot (Figure 1.6) 
(Lefkowitz, 2006; Pallister and Watson, 2010; Hall and Guyton, 2011). 
 
1.4.3.1  Extrinsic pathway 
 
 
The newer blood coagulation cascade model was well elaborated by Jerry B. Lefkowitz. 
Thrombin was portrayed as the center of the coagulation universe. All the coagulation 
factors involved in the hemostasis process feed into the regulation and control of 
thrombin generation, which then forms clots at the sites of vascular injury. Thrombin is 
a proteolytic enzyme derived from PT, which aids in blood clotting by catalyzing the 
conversion of Fib to fibrin. The modified intrinsic coagulation cascade, which is 
displayed in Figure 1.6, is different from the older one and lacks the significance of 
factor 12 (FXII) and prekallikren. Apparently, these proteins are not considered to play a 
crucial role in the coagulation process in vivo.  
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There are 2 major processes that could initiate the blood clotting mechanism. 
They are extrinsic and intrinsic pathways. Firstly, TF binds to FVII or activated FVIII 
(FVIIIa) in 1:1 ratio complex. A limited proteolysis process extends to TF / FVIIIa 
complex which activates factor 10 (FX) or factor 9 (FIX), further activating FX / FIX 
and activating serine proteases via the cleaving an activation peptide. Proteolysis is the 
hydrolysis process that involves the breakdown of proteins into smaller polypeptides. 
Once the extrinsic pathway is triggered, the activation of FX / FIX in the TF/ FVIIa 
complex is instantly inhibited by TF pathway inhibitor (TFPI), which is generated from 
endothelial cells. Freshly activated factor 9 (FIXa) subsequently adheres to its cofactor, 
factor VIIIa, upon the phospholipid surface to stimulate the tenase complex which 
results in the activation of FX to activated FX (FXa).  
Finally, the common pathway for thrombin activation is initiated via the 
activation of FXa. The activated FXa merges with the cofactor, activated factor 5 (FVa), 
and Ca on the phospholipid surfaces to construct prothrombinase complex. This 
complex eventually helps to convert PT to thrombin by cleaving the PT, which is the 
activation peptide. Thrombin activation will be generated to a very major extent by the 
extrinsic pathway, which is adequate and crucial to initiate the coagulation cascade 
which subsequently triggers and expands thrombin generation via the intrinsic pathway 
(Green, 2006; Leftowitz, 2006; Pallister and Watson, 2010). 
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1.4.3.2  Intrinsic pathway 
 
The activation of factor 11 (FXI) to activated FXI (FXIa) and more thrombin generated 
via FIXa and FVIIIa leads to the activation of FX, which is involved in the intrinsic 
pathway. FV and FVIII, which are partially proteolyzed or activated are known to be 
involved in and facilitated hemostasis process. Subsequently, the activation of FV and 
FVIII by thrombin triggers more mechanical action of the coagulation pathway by 
enhancing the bioactivity of tenase and prothrombinase complexes.  
As described in Table 1.6, factor I (FI / Fib) plays a crucial role in forming a 
fibrin clot to seal the injured area with fibrin meshes. Fib typically consists of 3 globular 
domains, which is the central E domain attached or flanked by 2 exactly alike identical 
D domains. At this stage, thrombin sticks to fibrinopeptides A and B, which are derived 
from the A alpha (α) and B beta (β) chains, to build a fibrin monomer. These monomers 
gather into protofibrils in a half-distributed manner, which is stabilized by the 
noncovalent interactions among fibrin molecules. Eventually, the photofibrils are 
obliquely organized into dense fibrin networks to form a temporary fibrin clot that is not 
covalently crosslinked.  
Nevertheless, to form a stable blood clot, thrombin needs to activate factor 13 
(FXIII) to the transglutaminase enzyme activated factor 13 (FXIIIa). Factor XIIIa will 
stimulate the glutamic acid and lysine side chains, producing a stable clot. Factor XIIIa 
is the fibrin stabilizing factor of the blood coagulation system that crosslinks with fibrin. 
Furthermore, factor XIIIa also plays a significant role towards tissue repair and the 
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angiogenesis process (Chandler, 2005; Green, 2006; Leftowitz, 2006; Pallister and 
Watson, 2010). 
 
             
 
 
Figure 1.6 Coagulation mechanism. Thrombin plays a vital role in generating 
cross-linked fibrin by cleaving Fib to fibrin and activating a few other coagulation 
factors. Thrombin also modulates other important cellular activities via protease-
activated receptors. Simultaneously, it will directly increase the platelet agglutination 
and the production of TXA2 to express adhesion molecules. This diagram was adapted 
from the source: Lefkowitz, J.B. (2006). Chapter 1. In hemostasis physiology. 
Coagulation pathway and physiology. JB Lippincott Co, Philadelphia, 3-12. 
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1.4.3.3  Coagulation factors 
 
Table 1.6 Coagulation factors aids in blood coagulation cascade 
Factor Name Source Pathway Description Function 
I Fib Liver Common Plasma Gp; Molecular Weight 
(MW)= 340 kilodaltons (kDa) 
Adhesive protein which aids in fibrin 
clot formation 
2 (II) PT Liver Common Vitamin K-dependent serine 
protease; MW= 72 kDa 
Presence in the activated form and the 
main enzyme of coagulation 
III TF Damaged 
cells and 
platelets 
Extrinsic and 
Intrinsic 
Known as thromboplastin; 
MW= 37 kDa 
Lipoprotein initiator of the extrinsic 
pathway 
IV Ca ions Bone and gut Entire 
process 
Required for coagulation factors 
to bind to phospholipid  
Metal cation that is important in 
coagulation mechanisms 
V Proaccererin   / 
Labile factor 
Liver and 
platelets 
Intrinsic and 
extrinsic 
MW = 330 kDa Cofactor for the activation of PT to 
thrombin (prothrombinase complex) 
VII Proconvertin 
(stable factor) 
Liver Extrinsic MW = 50 kDa; vitamin           
K-dependent serine protease 
With TF, it initiates the extrinsic 
pathway (FIX & FX) 
VIII Antihemophilic 
factor A (cofactor) 
Platelets and 
endothelium 
Intrinsic MW = 330 kDa Cofactor for the intrinsic activation of 
FX (which it forms tenase complex)  
 
 
 
Table 1.6. Continued 
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Informations were obtained and modified from (Green, 2006; Leftowitz, 2006; Pallister and Watson, 2010; Sonawani et al., 2010) 
IX Christmas factor / 
Antihemophilic 
factor B (plasma 
thromboplastin 
component)     
Liver Intrinsic MW = 50 kDa; vitamin K-
dependent serine protease 
The activated form is an enzyme for the 
intrinsic activation of FX (forms a 
tenase complex with FVIII) 
X Stuart-Prower 
factor (enzyme) 
Liver Intrinsic and 
extrinsic 
MW = 58.9 kDa; vitamin K-
dependent serine protease 
The activated form is the final enzyme 
for the common pathway activation of 
PT (forms prothrombinase complex 
with FV) 
XI Plasma 
thromboplastin 
antecedent 
Liver Intrinsic MW = 160 kDa; serine protease Activates the intrinsic activator of 
FIX 
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(XII) 
Hageman factor Liver Intrinsic; 
(activates 
plasmin) 
MW = 80 kDa; serine protease Initiates the activated partial 
thromboplastin time (APTT)-based 
intrinsic pathway; Activates FXI,  FVII 
and prekallikrein 
XIII Fibrin stabilizing 
factor 
Liver Retards 
fibrinolysis 
MW = 320 kDa; Crosslinks 
fibrin 
Transamidase which cross-links fibrin 
clot 
24 
 
1.4.4 Tertiary hemostasis 
 
Once the fibrin clot has been formed, the activated platelets will be well organized and 
take position to contract their intracellular actin or myosin cytoskeleton. The 
intracellular actin network will directly connect to the integrin GpIIbIIIa and Fib 
receptor internally. Subsequently, the external component of GpIIbIIIa will adhere to the 
fibrin network of the blood clot, making the clot compact and decreasing the clot volume 
slowly, which is called clot retraction. A plasminogen activator is a serine protease that 
converts plasminogen to plasmin to promote fibrinolysis by cutting and degrading the 
fibrin networks. Plasmin slashes off the fibrin meshes formed around the wounded area, 
resulting in the formation of other circulating fragments that are cleared by other 
proteases or by the kidney and liver. The clot resolution mechanism aid in clearing the 
injured and obstructed vessels, regenerating blood flow that is directed to the normal 
blood flow pathway. GpIIbIIIa disrupts the fibrin binding capacity with platelets and 
complete the clot resolution process (Hoffbrand, 2002; Leftowitz, 2006; Pallister and 
Watson, 2010). 
 
1.4.5 Wound healing 
 
Wound healing is an innate revitalizing response in tissue injuries, and the interaction of 
the cellular mechanical pathway events results in resurfacing, reconstitution and 
refurbishment of cells on injured surface area. The healing process can be explained in 3  
